Clinical trials: sponsored by Celgene
Multiple Myeloma
Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma
Define maximum tolerable dose of the combination lenalidomide, bendamustine, prednisone.
- Trial name
- NCT01002703
- Testing
- Lenalidomide, Bendamustine, Prednisone
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University of Leipzig
Breast Cancer
Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer
The lack of non-overlapping toxicities between the two drugs, the ease of all oral drug administration, and the possibility for antitumor synergy make exploration of this combination regimen attractive in women with previously…
- Trial name
- NCT00193102
- Testing
- Thalidomide, Capecitabine
- Volunteers
- 40 people
- Sponsor
- SCRI Development Innovations, LLC
Myelodysplastic Syndromes
Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality
The purpose of this study was to compare 2 doses (10 mg and 5 mg) of lenalidomide to that of placebo in subjects with red blood cell (RBC) transfusion-dependent low- or intermediate-1-risk IPSS MDS associated with a deletion…
- Trial name
- NCT00179621
- Testing
- Lenalidomide 5 mg, Lenalidomide 10 mg
- Where
- 38 sites in Belgium, France and 7 more
- Volunteers
- 205 people
- Sponsor
- Celgene Corporation
Atopic Dermatitis, Allergic Contact Dermatitis
Study of Apremilast in Atopic or Contact Dermatitis
The objective of this study is to evaluate the efficacy of apremilast in patients with recalcitrant atopic or contact dermatitis.
- Trial name
- NCT00931242
- Testing
- Apremilast
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Tufts Medical Center
Chronic Lymphocytic Leukemia, CLL
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
The study is a two-arm, multi-center trial of Revlimid® and Rituximab, for the frontline treatment of patients with Chronic Lymphocytic Leukemia (CLL) designed and conducted by the CLL Research Consortium (CRC).
- Conditions
- Chronic Lymphocytic Leukemia, CLL, Untreated, Front-line
- Trial name
- NCT00628238
- Testing
- Lenalidomide and Rituximab
- Where
- 5 sites in United States
- Volunteers
- 80 people
- Sponsor
- Chronic Lymphocytic Leukemia Research Consortium
Solid Tumors
Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors
This is a Phase 1/2, open-label, monocentric, dose-escalation study of lenalidomide in combination with cetuximab in subjects with solid tumors.
- Trial name
- TEXO (NCT01166035)
- Testing
- Lenalidomide, Cetuximab
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- Medical University Innsbruck
Waldenstrom Macroglobulinemia
Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia
The purpose of this research is to study how helpful thalidomide is in controlling the disease and to study any side effects from taking thalidomide.
- Trial name
- NCT00083707
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Arkansas
Leukemia
Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia
The purpose of this study is to evaluate the efficacy and safety of Thalidomide in patients with leukemia.
- Trial name
- NCT00083694
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Arkansas
Multiple Myeloma
D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma
This study has been designed to evaluate whether combination chemotherapy and "anti-angiogenesis" therapy with thalidomide is equal or superior to autologous transplantation for the treatment of multiple myeloma.
- Trial name
- NCT00083876
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- University of Arkansas
Idiopathic Pulmonary Fibrosis (IPF)
Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide
The goal of this study is to determine whether thalidomide can stop the progression of fibrosis in IPF. The primary objective of this study is to determine the safety, feasibility and efficacy of 400 mg of thalidomide…
- Trial name
- NCT00162760
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Johns Hopkins University
Cutaneous T Cell Lymphoma
Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma
Patients with cutaneous T cell lymphoma experience refractory and progressive disease despite current treatment, necessitating chronic disease management.
- Trial name
- REvMM2009 (NCT01132989)
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Florida Academic Dermatology Centers
Breast Neoplasms
Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer
The purpose of this study is to learn how breast cancer tumors respond to a drug called Abraxane followed by a combination of 3 chemotherapy drugs commonly used for breast cancer.
- Trial name
- NCT00110695
- Testing
- Nanoparticle albumin bound paclitaxel followed by FEC
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- NSABP Foundation Inc
Multiple Myeloma
Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
Subjects who qualify for participation will receive lenalidomide with or without dexamethasone in 4 week cycles until disease progression is documented or lenalidomide becomes commercially available for the indication of multiple…
- Trial name
- NCT00179647
- Testing
- lenalidomide, dexamethasone
- Where
- 69 sites in United States, Canada
- Volunteers
- 1,913 people
- Sponsor
- Celgene Corporation
Glioblastoma, Gliosarcoma
Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme
The purpose of this study is to find out if the combination of lenalidomide and radiation therapy is effective in controlling tumor growth in patients with newly-diagnosed supratentorial glioblastoma or gliosarcoma.
- Conditions
- Glioblastoma, Gliosarcoma, Malignant Gliomas
- Trial name
- NCT00165477
- Testing
- lenalidomide, Radiation
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Dana-Farber Cancer Institute
Lichen Planus
Pilot Study of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus
This study is designed to demonstrate to efficacy and safety of Apremilast 20mg oral administration twice daily over 12 weeks in subjects with moderate to severe lichen planus.
- Trial name
- NCT01041625
- Testing
- Apremilast (CC-10004)
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Virginia Clinical Research, Inc.
Small Cell Lung Cancer
Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.
The purpose of the study is to evaluate the objective tumor response rate of amrubicin or standard topotecan therapy when administered as second-line therapy to ED-SCLC patients who have chemotherapy sensitive recurrent or…
- Trial name
- NCT00319969
- Testing
- Amrubicin, Topotecan
- Where
- 47 sites in United States
- Volunteers
- 76 people
- Sponsor
- Celgene Corporation
Multiple Myeloma
A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma
To evaluate the response rate, response duration, and survival of patients treated with CC-5013 in a chronic dosing schedule versus a syncopated dosing schedule.
- Trial name
- NCT00051116
- Testing
- CC-5013
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Celgene Corporation
Radiculopathy
Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy
The purpose of this multicenter, double-blind, placebo-controlled study is to evaluate the efficacy and safety of lenalidomide in the treatment of painful lumbar radiculopathy.
- Trial name
- NCT00120120
- Testing
- Lenalidomide (CC-5013)
- Where
- 23 sites in United States
- Volunteers
- 181 people
- Sponsor
- Celgene Corporation
Colorectal Cancer
Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01)
This is an open-label, phase II study to evaluate the efficacy and safety of Abraxane in combination with Capecitabine in patients with metastatic colorectal cancer in the second or third line
- Trial name
- ABX067 (NCT00625573)
- Testing
- Abraxane
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Mt. Sinai Medical Center, Miami
Diffuse Large B-cell Lymphoma
A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
To evaluate the safety and efficacy of lenalidomide (Revlimid ®) in combination with dexamethasone in subjects with relapsed or refractory diffuse large B-cell lymphoma.
- Trial name
- NCT00474188
- Testing
- CC-5013 (lenalidomide), dexamethasone
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- Celgene Corporation